Valuation: Janux Therapeutics, Inc.

Market Cap 1.09B 976M 901M 815M 1.52B 104B 1.55B 10.75B 4.29B 54.33B 4.09B 4B 172B P/E 2026 *
-10.3x
P/E 2027 * -6.73x
Enterprise Value 191M 171M 158M 143M 267M 18.19B 271M 1.88B 751M 9.52B 717M 702M 30.15B EV / Sales 2026 *
6.49x
EV / Sales 2027 * 42x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week+4.51%
Current month+3.18%
1 month+5.19%
3 months+19.18%
6 months+26.36%
Current year+29.20%
1 week 16.42
Extreme 16.4242
18.62
1 month 16.13
Extreme 16.13
19.18
Current year 12.12
Extreme 12.12
20.31
1 year 12.12
Extreme 12.12
35.34
3 years 5.65
Extreme 5.65
71.71
5 years 5.65
Extreme 5.65
71.71
10 years 5.65
Extreme 5.65
71.71
Manager TitleAgeSince
Chief Executive Officer 67 01/06/2017
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 01/01/2021
Director TitleAgeSince
Director/Board Member 64 18/03/2021
Director/Board Member 55 18/03/2021
Director/Board Member 40 01/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Don

Founder

-123,840 0.2061%
08/07/26 Exercice

Founder

14,000 0.0233%
02/06/26 Sell

Executive/Senior Manager

-4,059 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%+4.51%-35.89%+196.18% 1.09B
+0.34%+1.12%+34.75%+61.06% 64.38B
+0.98%+2.68%+12.25%+82.98% 56.16B
+1.75%+2.01%+13.30%+103.69% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
-2.07%+42.73%+103.77%+88.74% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.64%-3.28%+21.10%-12.28% 23.57B
Average -0.33%+4.50%+43.41%+165.88% 39.38B
Weighted average by Cap. +0.00%+3.60%+48.92%+161.48%

Financials

2026 *2027 *
Net sales 29.42M 26.36M 24.31M 22M 41.14M 2.8B 41.81M 290M 116M 1.47B 110M 108M 4.64B 8.1M 7.25M 6.69M 6.06M 11.32M 771M 11.51M 79.84M 31.85M 404M 30.39M 29.75M 1.28B
Net income -107M -95.99M -88.56M -80.14M -150M -10.21B -152M -1.06B -421M -5.34B -402M -394M -16.92B -178M -159M -147M -133M -248M -16.92B -253M -1.75B -699M -8.86B -667M -653M -28.05B
Net Debt -899M -805M -743M -672M -1.26B -85.61B -1.28B -8.86B -3.54B -44.81B -3.37B -3.3B -142B -750M -671M -619M -561M -1.05B -71.39B -1.07B -7.39B -2.95B -37.36B -2.81B -2.75B -118B
Projected Income Statement - Annual - Janux Therapeutics, Inc.
Logo Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Employees
113
Date Price Change Volume
29/10/26 $17.83 -1.22% 905,868
28/10/26 $18.05 +4.58% 984,202
27/10/26 $17.26 +3.42% 687,229
26/10/26 $16.69 +0.18% 379,225
23/10/26 $16.66 -2.34% 378,883
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Janux Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
17.83USD
Average target price
33.81USD
Spread / Average Target
+89.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Janux Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. JANX Stock